Oksana Efremova

Dr. Oksana Efremova

Pirogov Russian National Research Medical University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
SGSergey Gavrilov
Sergey Gavrilov
AKAnatoly Karalkin
Anatoly Karalkin
NMNadezhda Mishakina
Nadezhda Mishakina
OEOksana Efremova
Oksana Efremova
AGAnastasia Grishenkova
Anastasia Grishenkova
The causes of chronic pelvic pain (CPP) in patients with pelvic venous disorder (PeVD) are not completely understood. Various authors consider dilation of pelvic veins (PeVs) and pelvic venous reflux (PVR) as the main mechanisms underlying symptomatic forms of PeVD. The aim of this study was to assess relationships of pelvic vein dilation and PVR with clinical manifestations of PeVD. This non-randomized comparative cohort study included 80 female patients with PeVD who were allocated into two groups with symptomatic (n = 42) and asymptomatic (n = 38) forms of the disease. All patients underwent duplex scanning and single-photon emission computed tomography (SPECT) of PeVs with in vivo labeled red blood cells (RBCs). The PeV diameters, the presence, duration and pattern of PVR in the pelvic veins, as well as the coefficient of pelvic venous congestion (CPVC) were assessed. Two groups did not differ significantly in pelvic vein diameters (gonadal veins (GVs): 7.7 ± 1.3 vs. 8.5 ± 0.5 mm; parametrial veins (PVs): 9.8 ± 0.9 vs. 9.5 ± 0.9 mm; and uterine veins (UVs): 5.6 ± 0.2 vs. 5.5 ± 0.6 mm). Despite this, CPVC was significantly higher in symptomatic versus asymptomatic patients (1.9 ± 0.4 vs. 0.7 ± 0.2, respectively; p = 0.008). Symptomatic patients had type II or III PVR, while asymptomatic patients had type I PVR. The reflux duration was found to be significantly greater in symptomatic versus asymptomatic patients (median and interquartile range: 4.0 [3.0; 5.0] vs. 1.0 [0; 2.0] s for GVs, p = 0.008; 4.0 [3.0; 5.0] vs. 1.1 [1.0; 2.0] s for PVs, p = 0.007; and 2.0 [2.0; 3.0] vs. 1.0 [1.0; 2.0] s for UVs, p = 0.04). Linear correlation analysis revealed a strong positive relationship (Pearson’s r = 0.78; p = 0.007) of CPP with the PVR duration but not with vein diameter. The grade of PeV dilation may not be a determining factor in CPP development in patients with PeVD. The presence and duration of reflux in the pelvic veins were found to be predictors of the development of symptomatic PeVD.

20 November 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
SGSergey Gavrilov
Sergey Gavrilov
NMNadezhda Y. Mishakina
Nadezhda Y. Mishakina
OEOksana Efremova
Oksana Efremova
KKKonstantin V. Kirsanov
Konstantin V. Kirsanov
Background: The efficacy and safety of gonadal vein embolization (GVE) with coils in the treatment of pelvic venous disease (PeVD) has not been fully investigated, and the outcomes after GVE do not always meet expectations of both doctors and patients. The study was aimed at assessing the incidence and causes of the complications after GVE with coils in patients with PeVD. Methods: This retrospective cohort study included 150 female patients with PeVD who underwent GVE with coils in 2000–2020. A total of 4975 patients with chronic pelvic pain (CPP) were examined, of which 1107 patients had the PeVD-related CPP and 305 underwent surgical or endovascular interventions on the gonadal veins. Complication rates were evaluated 30 days after GVE and classified according to the Society for Interventional Radiology (SIR) adverse event classification system. The pain severity before and after GVE was assessed using a visual analogue scale (VAS). All patients underwent duplex ultrasound after GVE, while patients with persisting pain syndrome and suspected perforation of the gonadal vein were also evaluated using computed tomographic venography. Results: At 30 days after GVE, the CPP was decreased in 109 (72.6%) patients (from 8.2 ± 1.5 at baseline to 1.7 ± 0.8 scores, p = 0.0001) and persisted in 41 (27.4%) patients (mean change from 8.1 ± 0.7 at baseline to 7.8 ± 0.4 scores; p = 0.71). Post-embolic syndrome (PES) occurred in 22% of patients and was completely resolved in 1 month after GVE. The efficacy of GVE in the CPP relief after resolving PES was 94.6%. The GVE complications were identified in 52 (34.6%) patients. Minor complications included access-site hematoma (4%) and allergic reactions (1.3%), and major complications included protrusion of coils (5.3%), thrombosis of the parametrial/uterine veins (21.3%) and deep veins of the calf (2.7%). Conclusions: Gonadal vein embolization with coils in the treatment of PeVD is associated with the development of specific complications and adverse events. The most common complication was pelvic vein thrombosis. Post-embolization syndrome should be considered as an adverse event of this procedure.

Verified
Journal Article
Open access
PDF file
SGSergey Gavrilov
Sergey Gavrilov
GKGennady Vladimirovich Krasavin
Gennady Vladimirovich Krasavin
NMNadezhda Yurievna Mishakina
Nadezhda Yurievna Mishakina
OEOksana Efremova
Oksana Efremova
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Objective. To evaluate the incidence of post-embolization syndrome (PES) and the effect of venoactive therapy on its development, severity, and duration after endovascular embolization of gonadal veins (EEGV) with coils in patients with pelvic congestion syndrome (PCS). Materials and Methods. We analyzed the outcomes of EEGV with coils in 70 female patients who received (n = 38; group 1) or did not receive (n = 32; group 2) treatment with a venoactive drug (VAD) before and after the procedure. Assessments of the EEGV efficacy and for possible signs of PES were done on days 1, 5, 10, 15, 20, and 30 after the intervention. All patients underwent transvaginal and transabdominal duplex ultrasound scanning (DUS) after EEGV. In addition, patients with PES were examined using the computed tomography of the pelvic veins in the postprocedural period. Results. Technical success of EEGV was achieved in 100% of patients. Pelvic venous pain (PVP) reduction after EEGV was observed in 77.1% of patients. The PES was diagnosed in 18.6% of cases (10.5% in group 1 vs. 28.1% in group 2, p > 0.05). In three patients of group 1, the protrusion of coils was suspected and eventually verified during the resection of the left gonadal vein with coils. The group 1 patients had less severe post-embolization pain (6.2 ± 0.4 vs. 7.8 ± 0.3 scores in group 2; p = 0.009) and three times shorter duration of PES (5.0 ± 1.2 vs. 16.2 ± 2.7 days; p = 0.003). No significant differences in the diameters of gonadal veins, side of embolization, and number of coils were revealed between patients with and without PES. The rate of parametrium vein thrombosis was found to be significantly higher in patients with PES than in those without PES (30.7% vs. 18.5%, respectively; p < 0.05). Conclusion. The PES is a frequent complication of EEGV with coils and occurs in 18.6% of patients. Venoactive treatment does not effect the incidence of this complication but reduces the PES severity and duration.

1 January 2019 in Journal of Venous Disorders
Verified
Journal Article
Closed access
PDF file
ASA. V. Sazhin
A. V. Sazhin
ILI. S. Lebedev
I. S. Lebedev
SGSergey Gavrilov
Sergey Gavrilov
TNT. V. Nechai
T. V. Nechai
DSD. I. Shishkina
D. I. Shishkina
AKA. I. Kirienko
A. I. Kirienko

24 March 2023 in Journal of Venous Disorders
Verified
Journal Article
Closed access
IZIgor A. Zolotukhin
Igor A. Zolotukhin
YSYu.M. Stoyko
Yu.M. Stoyko
ISIgor Suchkov
Igor Suchkov
OGO.V. Golovanova
O.V. Golovanova
OEOksana Efremova
Oksana Efremova
AKA.A. Kamaev
A.A. Kamaev
Adherence to compression therapy is low in many patients, especially in warm weather. Venoactive drug (VAD) therapy alone may be an option in patients with symptomatic chronic venous disease (CVD). Objective. To compare VAD therapy and compression therapy in symptomatic CVD patients during warm season. Material and methods. A comparative non-randomized study included 60 patients with CVD class C1S, C2S and C3S. Patients were recruited between May and September. VAD containing micronized diosmin 900 mg and hesperidin 100 mg one tablet per day for 90 days was prescribed in 41 patients (main group). Compression stockings were recommended in 19 patients (control group). End-points were discomfort in the lower legs related to CVD symptoms, quality of life (QoL) and venous symptoms. Results. Legs discomfort decreased from 52±22 to 32±19 (p<0.0001) after VAD therapy and from 49±21 to 42±17 (p=0.02) after compression therapy. VAD therapy resulted more significant regression of discomfort (38% and 14%, respectively, p<0.001). QoL improved from 64±16 to 78±12 (p<0.0001) after VAD treatment and from 72±14 to 77±8 (p=0.02) after compression therapy. Mean improvement was 22% and 5%, respectively (p<0.001). All venous symptoms decreased significantly after medical therapy. In the main group, 32 (78%) patients were adherent to VAD treatment, and only 5 (26.4%) patients complied with compression therapy. Conclusion. VAD therapy alone significantly reduces venous symptoms and improves QoL in warm weather. VAD treatment alone can be recommended as an alternative to compression therapy in warm season.

Verified
Journal Article
Open access
PDF file
SMSevara Mirakhmedova
Sevara Mirakhmedova
AAAmirkhan Amirkhanov
Amirkhan Amirkhanov
ESEvgenii Seliverstov
Evgenii Seliverstov
OEOksana Efremova
Oksana Efremova
IZIgor A. Zolotukhin
Igor A. Zolotukhin
Background: There are no data on the daily regimen of compression therapy in patients with chronic venous disease. This systematic review aimed to establish the optimal daily duration of compression treatment. Methods: A systematic search of CENTRAL and MEDLINE was performed to identify RCTs, non-RCTs, reviews, systematic reviews, meta-analyses, and guidelines evaluating the use of compression regimens in the treatment of varicose veins. Results: Thirty-two RCTs, three non-RCTs, four observational studies, and two crossover trials reporting the duration and regimes of compression treatment fulfilled the inclusion criteria. The daily duration of compression was reported in patients after invasive treatment, for venous ulcer treatment, in patients with venous symptoms. The quality of the studies varied. We could not conduct a meta-analysis due to the heterogeneity of the research data and their quality. Twenty-three studies reported results of compression usage after invasive procedures. Eight studies reported daily duration regimens in patients with venous ulcers. Nine studies reported the impact of compression on venous symptoms and/or edema or limb volume change. One study was conducted to assess if compression improves QoL in venous patients. While there was a clear difference found in the daily duration depending on the clinical scenario, no data in support of exact regimens were found. Conclusions: There are no reliable data supporting exact daily regimens of compression treatment in various cohorts of CVD patients.